Purespring Names Haseeb Ahmad as CEO to Lead Kidney Therapy Innovations
Company - People | Mar 12, 2025 | Syncona
Purespring Therapeutics, a leader in kidney disease treatment, has appointed Haseeb Ahmad as CEO to spearhead its efforts in pioneering gene therapies. Ahmad, with over 25 years in life sciences, moves from President of Novartis Europe to his new role after Purespring's successful $105 million Series B financing. Known for its breakthrough in targeting podocytes for kidney disease gene therapies, Purespring is focused on expanding its transformative treatments and pursuing new partnerships. Ahmad replaces Julian Hanak, who led critical milestones, including the Series B funding. Purespring plans to advance various kidney disease programs, with Phase I/II trials for IgA Nephropathy upcoming.
Sectors
- Biotechnology
- Healthcare
Geography
- United Kingdom – Purespring is headquartered in London, making the UK a primary geographical focus in the article.
- Europe – Haseeb Ahmad was previously President of Novartis Europe, indicating a broader European relevance.
Industry
- Biotechnology – Purespring is actively engaged in developing genetic therapies, placing the company firmly within the biotechnology sector.
- Healthcare – Given Purespring's focus on treating kidney diseases, the healthcare sector is a relevant classification.
Financials
- $105 million – Amount raised in Purespring's Series B financing round.
- $15 billion – Revenue overseen by Haseeb Ahmad during his tenure as President of Novartis Europe.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Purespring Therapeutics | Target Company | Company | A biotechnology company focusing on treating kidney diseases with a gene therapy platform. |
| Haseeb Ahmad | Incoming CEO | Person | Newly appointed CEO of Purespring, previously President of Novartis Europe. |
| Julian Hanak | Outgoing CEO | Person | Former CEO of Purespring who led the company through significant achievements, including a successful Series B financing. |
| Syncona Limited | Investor | Company | Founding investor of Purespring, supporting its biotech advancements. |
| Sofinnova Partners | Investor | Company | Led the Series B financing round for Purespring. |
| Gilde Healthcare | Investor | Company | Participated in the Series B financing round for Purespring. |
| Forbion | Investor | Company | Contributed to the Series B financing of Purespring. |
| British Patient Capital | Investor | Company | An investor in Purespring's funding rounds. |